In a pilot study, a method of imaging in primary aldosteronism was developed with the use of an aldosterone synthase (CYP11B2)–specific ¹⁸F-labeled radioligand for use with positron-emission tomography. Full study results: nej.md/4rypvto #MedSky #EndoSky

Privileged to take part in the 1st #VHL Alliance Research Forum in Charlotte, NC. Together, we explored future opportunities in VHL #CancerResearch. Thank you, VHL Alliance and the Rath Family, for this inspiring meeting! We will continue studying VHL- #PNET and #PPGL! 🚀 #RareDisease #Oncology

This NET Cancer Day, join us in raising awareness of NET signs and symptoms. Patients, caregivers, and healthcare professionals are encouraged to take the survey and share their experiences: https://loom.ly/qieCY4w #NETCancer #NETCancerDay #PatientAdvocacy #NANETS

Today, we stand with the global community in recognising everyone affected by neuroendocrine cancer. At Endocrine-Related Cancer, we remain committed to publishing high-quality research that advances understanding of NETs to optimise patient care. 🔗 lnkd.in/eBY6uA_r #WorldNeuroendocrineCancerDay

🎉 Excited to share our new publication! Targeted inhibition of netrin–DCC axis with NP137 reverses netrin-driven survival in vitro & reduces high-grade pancreatic NEN progression in vivo. Potential therapeutic strategy for aggressive PNENs? bit.ly/435pKBx @endocancer.bsky.social